Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
5-day change
1st Jan Change
22.3
USD
-2.53%
-0.89%
-18.94%
Presenter SpeechMatthew Sykes (Analysts)Good morning, everyone. This is Matt Sykes, Senior Lif...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Earnings Flash (VCYT) VERACYTE Posts Q1 Revenue $96.8M, vs. Street Est of $93.4M
May. 07
MT
Transcript : Veracyte, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024
May. 07
CI
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating
Apr. 15
MT
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating
Feb. 26
MT
Sector Update: Health Care Stocks Mixed Premarket Friday
Feb. 23
MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating
Feb. 23
MT
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell
Feb. 23
MT
Transcript : Veracyte, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Feb. 22
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M
Feb. 22
MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024
Feb. 22
CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 22
CI
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 22
CI
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors
Feb. 13
CI
Veracyte Closes $70 Million C2i Genomics Acquisition
Feb. 06
MT
Veracyte, Inc. completed the acquisition of C2i Genomics, Inc.
Feb. 04
CI
Transcript : Veracyte, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
Jan. 08
Veracyte, Inc. Provides Preliminary Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2023
Jan. 08
CI
Veracyte, Inc. has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.
Jan. 07
CI
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
Dec. 04
MT
Veracyte Says New Data Backs Utility of Decipher Genomic Classifier to Treat, Manage Prostate Cancer
Dec. 01
MT
Morgan Stanley Trims Price Target on Veracyte to $22 From $23, Maintains Underweight Rating
Nov. 10
MT
Veracyte's Q3 Loss Widens, Revenue Increases; Raises 2023 Revenue Outlook
Nov. 08
MT
Earnings Flash (VCYT) VERACYTE Reports Q3 Revenue $90.1M, vs. Street Est of $84.4M
Nov. 07
MT
Transcript : Veracyte, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
More about the company
Last Close Price
22.3
USD
Average target price
29.83
USD
Spread / Average Target
+33.78%
Consensus
1st Jan change
Capi.
-18.94% 1.7B -31.06% 9.41B +27.31% 2.9B -14.31% 2.16B +73.13% 1.51B +30.25% 814M -1.97% 760M -26.73% 529M +5.17% 312M -17.46% 183M
Bio Diagnostics & Testing
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1